Clinical Trial Update: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor [Phase 3]

View source ↗

Summary

Phase 3 trial update studying octreotide acetate with interferon alfa-2b or bevacizumab in metastatic or locally advanced high-risk neuroendocrine tumors; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neuroendocrine Tumor
• Gastric Neuroendocrine Tumor
• Neuroendocrine Tumor

Drugs mentioned

• Avastin (bevacizumab)
• Intron A (interferon alfa-2b)
• Sandostatin (Octreotide acetate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1 | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2016-04-28